Viewing data from:

TIGAN

NDA

TRIMETHOBENZAMIDE HYDROCHLORIDE | N017531 | KING PHARMACEUTICALS LLC

1 strength0 unique patents0 unique exclusivities

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

No clinical trials found on ClinicalTrials.gov for this drug

Medicare Part B Spending

CMS physician-administered drug spending for Tigan (2023)

Total Spending

$59K

Total Claims

1,445

Beneficiaries

440

ASP Price

—

HCPCS: J3250 — Injection, trimethobenzamide hcl, up to 200 mg

Source: CMS Medicare Part B Spending by Drug (2023). Shows physician-administered drug costs.

API Supply Chain1 active DMF2 inactive

1 active API supplier hold Drug Master Files for this ingredient. Limited supplier base — potential supply chain risk.

EMCURE PHARMACEUTICALS LTDTRIMETHOBENZAMIDE HYDROCHLORIDE USP

DMF 269502013

FABBRICA ITALIANA SINTETICI SPAInactiveTRIMETHOBENZAMIDE HYDROCHLORIDE

DMF 77211988

DK PHARMA CHEM PVT LTDInactiveTRIMETHOBENZAMIDE HYDROCHLORIDE USP

DMF 274282014

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

4 letters from Drugs@FDA

Source: Drugs@FDA application documents.

Products (1)

#006 — 300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RLD

0 patents0 exclusivities▴

CAPSULE;ORAL | Approved: Dec 13, 2001

No patent or exclusivity listings for this strength.